COMMUNIQUÉS West-GlobeNewswire

Avance Clinical to Meet European Biotechs at ESMO Congress 2026 and Appoints Wendy Hamon as Senior Vice President, Oncology Center of Excellence
21/10/2026
Executive Medical Director Dr George Peoples to discuss oncology programs from preclinical through Phase II in Madrid ADELAIDE, Australia, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Avance Clinical, a global full-service CRO [...]
Kylo Peptides Marks Record Month as Brand Searches Nearly Triple
21/10/2026
Sheridan, Wyoming, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Kylo Peptides [ https://kylopeptides.com/ ], a research peptide supplier, recorded its highest month of brand search interest in September 2026. Estimated US searches [...]
ONWARD Medical Announces the Appointment of Fouad Azzam to its Board of Directors
21/10/2026
Fouad Azzam is a Partner with EQT Life Sciences, bringing extensive experience investing in and supporting fast-growing medical technology and life sciences companies EINDHOVEN, the Netherlands, Oct. 21, 2026 (GLOBE [...]
First Patient Treated in the C-FLASH-01 ConformalFLASH® Clinical Trial
21/10/2026
First Patient Treated in the C-FLASH-01 ConformalFLASH ® Clinical Trial Louvain-la-Neuve, Belgium, October 21, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and [...]
Premier patient traité dans le cadre de l’essai clinique C-FLASH-01 sur ConformalFLASH®
21/10/2026
Premier patient traité dans le cadre de l’essai clinique C-FLASH-01 sur ConformalFLASH ® Louvain-la-Neuve, Belgique, le 21 octobre 2026 – IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’ [...]
F2G and Shionogi Report Data from Global Phase 3 OASIS Study Evaluating Investigational Oral Olorofim Versus AmBisome® Followed by Standard of Care in Invasive Aspergillosis in Late-Breaking Oral Presentation at IDWeek 2026
21/10/2026
Oral olorofim was non-inferior to AmBisome ® followed by standard of care (AmBisome ® +SOC), with Day 42 all-cause mortality of 23.8% for olorofim versus 24.3% for AmBisome ® +SOC in patients with invasive aspergillosis [...]
Teknova Announces Pricing of $40 Million Public Offering of Common Stock
21/10/2026
HOLLISTER, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, [...]
Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stock
21/10/2026
WATERTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments [...]
HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China
21/10/2026
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., Oct. 20, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that further to its announcement on [...]
Ascentage Pharma’s Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL
21/10/2026
ROCKVILLE, Md., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development [...]
Telix Reports Third Quarter 2026 Financial Performance
21/10/2026
MELBOURNE, Australia and INDIANAPOLIS, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides a financial update on its commercial and operational performance for the [...]
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution
20/10/2026
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution 20. Oct 2026 / 23:54 CET/CEST, transmitted by [...]
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution
20/10/2026
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution 20. Oct 2026 / 23:52 CET/CEST, transmitted by [...]
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution
20/10/2026
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution 20. Oct 2026 / 23:51 CET/CEST, transmitted by [...]
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution
20/10/2026
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution 20. Oct 2026 / 23:50 CET/CEST, transmitted by [...]
BioSyent to Present at Planet MicroCap Toronto
20/10/2026
MISSISSAUGA, Ontario, Oct. 20, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be attending the Planet MicroCap investor conference in Toronto, Ontario from [...]
Surrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 Million
20/10/2026
Proceeds strengthen balance sheet and provide expected cash runway into 2029 to advance SZN-8141 and SZN-8143 SOUTH SAN FRANCISCO, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Surrozen or the Company) ( [...]
STERIS to Host a Conference Call for Fiscal 2027 Second Quarter on November 5, 2026
20/10/2026
DUBLIN, IRELAND, Oct. 20, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2027 second quarter results at 9:00 a.m. ET [...]
Rapid Micro Biosystems to Participate at the PDA Pharmaceutical Microbiology Conference 2026
20/10/2026
LEXINGTON, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to [...]

Pages

Other news

Promaxo Announces Closing of Series C Financing and $100M Credit Facility

Contenu:

The growth capital will expand manufacturing capacity, reduce backlog, and support new regulatory filings

ProKidney to Host Virtual KOL Event to Recap Mechanism of Action Data Presented at ASN Kidney Week and Provide a Corporate Update

Contenu:

WINSTON-SALEM, N.C., Oct. 22, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp.

BreathiZen Introduces BreathiZen Spray - A New Multi-Ingredient Dietary Supplement For Your Respiratory Wellness

Contenu:

BreathiZen is a once-daily oral spray that brings together botanical extracts, an enzyme preparation, and selected nutrients in a 60 ml bottle designed to fit easily into an adult wellness routine.

New York, Oct. 22, 2026 (GLOBE NEWSWIRE) --

RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026

Contenu:

Company to host conference call on November 5, 2026, at 4:30 p.m. ET

BridgeBio to Report Third Quarter 2026 Financial Results and Commercial Updates on October 29, 2026 at 4:30 pm ET

Contenu:

PALO ALTO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc.

Ernexa Therapeutics Highlights ERNA-101’s Path Toward the Clinic and Differentiated Cell Therapy Platform in New “What This Means” Segment

Contenu:

Leadership discusses recent FDA engagement, the technology underlying ERNA-101 and the development strategy supporting planned first-in-human clinical evaluation

SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome

Contenu:

TEL AVIV, Israel, Oct. 22, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its subsidiary, NeuroThera Labs Inc.